Table:
Age, sex and geometric mean 50% plaque reduction neutralization test (PRNT50) titres vs. Wild-type (WT) or Omicron BA.1 variant 3–5 weeks post vaccine
| Exposure group | n | Mean Age (SD) | Age range | Male: female | WT GMT | Omicron GMT | WT: Omicron Fold GMT reduction | No (%) of sera with detectable antibody to Omicron | No. above PRNT50 threshold of protection (1:25.6) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Omicron | Wild-type | |||||||||
| BNT162b2 (2 doses) | 31 | 51.7(14.4) | 25–76 | 17:14 | 218.8 | 7.0 | 31.3 | 8/31 (25.8%) | 2/31 | 30/31 |
| BN162b2 (3 doses) | 25 | 50.6(14.9) | 22–72 | 14:11 | 320 | 77.8 | 4.1 | 25/25 (100.0%) | 22/25 | 25/25 |
| CoronaVac (2 doses) | 30 | 52.1(8.2) | 39–73 | 10:20 | 32.5 | 5 | 6.5 | 0/ 30 (0.0%) | 0/30 | 14/30 |
| CoronaVac (2 dose+CoronaVac booster) | 30 | 50.5(8.8) | 36–73 | 8:22 | 65 | 8.9 | 7.3 | 19/30 (63.3%) | 1/30 | 25/30 |
| CoronaVac (2 dose+BNT162b2 booster) | 30 | 50.4(9.3) | 31–66 | 13:17 | 305.5 | 59.2 | 5.2 | 30/30 (100.0%) | 24/30 | 30/30 |
| SARS-CoV-2 Convalescent (day 143–196 days) | 30 | 48.9(15.8) | 20–72 | 13:17 | 85.7 | 8.1 | 10.6 | 12/30 (40.0%) | 1/30 | 29/30 |
| SARS-CoV-2 convalescent + BNT162b2 (1 dose) | 30 | 49.8(14.8) | 20–71 | 15:15 | 320 | 130 | 2.5 | 30/30 (100.0%) | 29/30 | 30/30 |
| SARS-CoV-2 convalescent + CoronaVac (1 dose) | 28 | 55.0(10.6) | 29–81 | 14:14 | 237.8 | 29.7 | 8.0 | 27/28 (96.4%) | 18/28 | 28/28 |